Tag Archives: Cory Kasimov

J.P. Morgan Issues a Buy Rating on Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Cory Kasimov from J.P. Morgan assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed last Monday at $226.49, close to its 52-week high of $233.26. According to TipRanks.com, Kasimov

J.P. Morgan Reaffirms Their Hold Rating on Regeneron (REGN)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGN – Research Report) yesterday. The company’s shares closed last Monday at $378.93. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a

Incyte (INCY) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Incyte (INCY – Research Report) yesterday. The company’s shares closed last Monday at $77.10. According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a

J.P. Morgan Sticks to Their Hold Rating for Clovis Oncology (CLVS)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Clovis Oncology (CLVS – Research Report). The company’s shares closed last Monday at $8.70. According to TipRanks.com, Kasimov is a 4-star analyst with an average

Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (NASDAQ: GBT), Intuitive Surgical (NASDAQ: ISRG) and Kodiak Sciences (NASDAQ: KOD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT – Research Report), Intuitive Surgical (ISRG – Research Report) and Kodiak Sciences (KOD – Research Report). Global Blood Therapeutics (GBT) J.P.

ACADIA Pharmaceuticals (ACAD) Received its Third Buy in a Row

After Cowen & Co. and Needham gave ACADIA Pharmaceuticals (NASDAQ: ACAD) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals yesterday. The company’s shares